/ Articles / Peptides Demystified
BPC-157 vs TB-500: What The Evidence Actually Shows
Two different molecules, two different stories, and one shared problem: almost no human data.
KILLER*.HEALTH editorial · 3 min read · Updated October 2, 2026
They get named in the same breath and talked about online as two brands of the same thing. They are not the same thing. They are different molecules with different proposed jobs — and the honest headline for both is the same: interesting animal research, almost no human evidence.
BPC-157 — the local story
BPC-157 is a synthetic 15-amino-acid sequence modelled on a fragment of a larger protein found in human gastric juice — a protein your stomach makes to protect its own lining. Most of the published research comes from one university group in Zagreb.
What the animal and lab literature describes:
- New blood-vessel growth into damaged tissue.
- Growth-hormone receptor upregulation on tendon cells, the most-cited explanation for the tendon results in rats.
- Nitric-oxide pathway effects.
- Lower inflammatory signalling.
- Stability in stomach acid, which is why researchers have studied it for gut conditions.
The word doing the work in all of that is local: in animal models BPC-157 behaves like something that acts where the damage is.
TB-500 — the systemic story
TB-500 is a synthetic seven-amino-acid fragment (LKKTETQ) of thymosin beta-4, a 43-amino-acid protein found in most of your cells. Be precise about this, because the internet is not: TB-500 is not thymosin beta-4. It is a short piece of it.
What the literature on thymosin beta-4 describes:
- Actin binding — actin is the scaffolding protein cells use to change shape and move.
- Repair-cell migration toward damaged tissue.
- Blood-vessel growth, by a different route than BPC-157.
- Lower inflammation in muscle, heart and eye models.
The word here is systemic. But note what is being described: most of that research is on the full-length protein, not the fragment.
Why they get mentioned together
The popular rationale is that a local repair signal and a whole-body one might complement each other. That is a hypothesis, not a finding. No study has tested the two together in people, and combining two poorly characterised compounds adds unknowns rather than removing them. This site does not recommend combining them, or using either.
What the evidence actually is
Be honest about this, because most pages on this topic are not.
| BPC-157 | TB-500 | |
|---|---|---|
| Animal studies | Many, mostly one research group, consistent faster-healing signal | Mostly on full-length thymosin beta-4 |
| Human studies | A handful of small, uncontrolled reports | FDA says it has found no human exposure data for the fragment |
| Large randomized trials | None | None |
| FDA-approved | No | No |
That gap — a consistent animal signal and essentially no human trials — is the whole story. Until someone runs the trials, nobody can tell you whether either compound helps people heal, or what it costs them in risk.
Risks
- Unknown long-term safety. FDA's safety summaries for both cite possible immune reactions (immunogenicity), peptide impurities and too little information to know whether they cause harm.
- Cancer. Both promote blood-vessel growth in animal studies. That makes a history of cancer a serious reason for caution — you do not want to improve blood supply to a tumour.
- Pregnancy and breastfeeding. No data.
- Product quality. Neither is an approved drug, so products sold online are unregulated and may not contain what the label says.
Regulatory status, in plain words
- Neither is FDA-approved for any use.
- Both were placed in FDA's "category 2" for compounding — bulk substances that may present significant safety risks. The nominations were later withdrawn, and in April 2026 FDA moved both to the "nominated but withdrawn" list on its significant safety risks page, which still sets out its concerns. Withdrawal is not approval.
- In July 2026 FDA's Pharmacy Compounding Advisory Committee reviewed both. It voted 8–6, with one abstention, to recommend adding BPC-157 to the list of substances pharmacies may compound, against FDA staff's recommendation. Committee votes are not binding; as of 2 October 2026 FDA has not added either compound.
- Both are prohibited in sport by the World Anti-Doping Agency.
What to do with this
If an injury is not healing, start with the Recovery Kill: graded rehab, sleep, protein, a real diagnosis. If you are thinking about either compound, take this page to a licensed clinician, tell them your full history, and ask what is known about the risks for you specifically. If you have had a reaction to any product, tell your clinician and report it to FDA MedWatch.